Cardioprotective effects of rutin via alteration in TNF-α, CRP, and BNP levels coupled with antioxidant effect in STZ-induced diabetic rats

Molecular and Cellular Biochemistry

Volumn 420, Issue 1-2, 2016, Pages 65-72

  Saklani, Ravi ^a   Gupta, Suresh Kumar ^a   Mohanty, Ipseeta Ray ^b   Kumar, Binit ^c   Srivastava, Sushma ^a   Mathur, Rajani ^a  

^a UNIVERSITY OF DELHI   (India)

^b Mahatma Gandhi Memorial Medical College   (India)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Diabetes; Diabetic cardiomyopathy; Diabetic complications; Rutin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; RUTOSIDE; TUMOR NECROSIS FACTOR; ANTIOXIDANT; BRAIN NATRIURETIC PEPTIDE; CARDIOTONIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CONTROLLED STUDY; DEGENERATION; DIABETIC CARDIOMYOPATHY; DRUG EFFECT; DRUG MECHANISM; ECG ABNORMALITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART ELECTROPHYSIOLOGY; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; HYPERGLYCEMIA; INFLAMMATION; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; C-REACTIVE PROTEIN; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; FEMALE; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; RATS; RATS, WISTAR; RUTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84979236343     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-016-2767-1     Document Type: Article

References (43)

1. van Dieren DS, Beulens JW, van der Schouw YT, Grobbee DE, Neal B (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17(Suppl 1):S3–S8. doi:10.1097/01.hjr.0000368191.86614.5a
2. Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11:31–39. doi:10.1007/s11154-010-9131-7
3. Huynh K, Bernardo BC, McMullen JR, Ritchie RH (2014) Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 142:375–415. doi:10.1016/j.pharmthera.2014.01.003
4. Cai L, Kang YJ (2001) Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 1:181–193. doi:10.1385/CT:1:3:181
5. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058–1070. doi:10.1161/CIRCRESAHA.110.223545
6. Remmen HV, Williams MD, Guo Z et al (2001) Knockout mice heterozygous for Sod2 show alterations in cardiac mitochondrial function and apoptosis. Am J Physiol Heart Circ Physiol 281:H1422–H1432
7. Pankuweit S, Ruppert V, Maisch B (2004) Inflammation in dilated cardiomyopathy. Herz 29:788–793. doi:10.1007/s00059-004-2626-9
8. Silva D, Pais de Lacerda A (2012) High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. Rev Port Cardiol 31:733–745. doi:10.1016/j.repce.2012.09.006
9. 2+ ATPase. Crit Care Med 39:984–992. doi:10.1097/CCM.0b013e31820a91b9
10. Janczewski AM, Kadokami T, Lemster B et al (2003) Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-α. Am J Physiol Heart Circ Physiol 284:H960–H969. doi:10.1152/ajpheart.0718.2001
11. Rouet-Benzineb P, Buhler JM, Dreyfus P et al (1999) Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1:337–352. doi:10.1016/S1388-9842(99)00048-3
12. Chua LS (2013) A review on plant-based rutin extraction methods and its pharmacological activities. J Ethnopharmacol 150:805–817. doi:10.1016/j.jep.2013.10.036
13. Kamalakkannan N, Prince PSM (2006) Antihyperglycaemic and antioxidant effect of rutin, a polyphenolic flavonoid, in streptozotocin-induced diabetic wistar rats. Basic Clin Pharmacol Toxicol 98:97–103. doi:10.1111/j.1742-7843.2006.pto_241.x
14. Hao G, Dong Y, Huo R, Wen K, Zhang Y, Liang G (2016) Rutin inhibits neuroinflammation and provides neuroprotection in an experimental rat model of subarachnoid hemorrhage, possibly through suppressing the Rage-NF-kappaB inflammatory signaling pathway. Neurochem Res 41:1496–1504. doi:10.1007/s11064-016-1863-7
15. Wu WB, Hung DK, Chang FW, Ong ET, Chen BH (2012) Anti-inflammatory and anti-angiogenic effects of flavonoids isolated from Lycium barbarum Linnaeus on human umbilical vein endothelial cells. Food Funct 3:1068–1081. doi:10.1039/C2FO30051F
16. Gupta SK, Dongare S, Mathur R et al (2015) Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocin-induced diabetic cardiomyopathy in rats. Mol Cell Biochem 408:63–72. doi:10.1007/s11010-015-2483-2
17. Gupta SK, Kumar B, Nag TC et al (2011) Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther 27:123–130. doi:10.1089/jop.2010.0123
18. Kumar B, Gupta SK, Nag TC et al (2014) Retinal neuroprotective effects of quercetin in streptozotocin-induced diabetic rats. Exp Eye Res 125:193–202. doi:10.1016/j.exer.2014.06.009
19. Kumar B, Gupta SK, Srinivasan BP et al (2012) Hesperetin ameliorates hyperglycemia induced retinal vasculopathy via anti-angiogenic effects in experimental diabetic rats. Vascul Pharmacol 57:201–207. doi:10.1016/j.vph.2012.02.007
20. Kumar B, Gupta SK, Srinivasan BP et al (2013) Hesperetin rescues retinal oxidative stress, neuroinflammation and apoptosis in diabetic rats. Microvasc Res 87:65–74. doi:10.1016/j.mvr.2013.01.002
21. Kannan MM, Quine SD (2011) Ellagic acid ameliorates isoproterenol induced oxidative stress: evidence from electrocardiological, biochemical and histological study. Eur J Pharmacol 659:45–52. doi:10.1016/j.ejphar.2011.02.037
22. Umbarkar P, Singh S, Arkat S et al (2015) Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy. Free Radic Biol Med 87:263–273. doi:10.1016/j.freeradbiomed.2015.06.025
23. Guo Z, Qin Z, Zhang R et al (2012) Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats. Eur J Pharmacol 685:116–125. doi:10.1016/j.ejphar.2012.04.010
24. Hamblin M, Friedman DB, Hill S et al (2007) Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol 42:884–895. doi:10.1016/j.yjmcc.2006.12.018
25. Felicio JS, Koury CC, Carvalho CT et al (2015) Present insights on cardiomyopathy in diabetic patients. Curr Diabetes Rev 12:1–12. doi:10.2174/1573399812666150914120529
26. Asbun J, Villarreal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47:693–700. doi:10.1016/j.jacc.2005.09.050
27. Epshteyn V, Morrison K, Krishnaswamy P et al (2003) Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients With diabetes. Diabetes Care 26:2081–2087. doi:10.2337/diacare.26.7.2081
28. Li CJ, Lv L, Li H, Yu DM (2012) Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol 11:73. doi:10.1186/1475-2840-11-73
29. Mano Y, Anzai T, Kaneko H et al (2011) Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J 75:1717–1727. doi:10.1253/circj.CJ-10-1199
30. Mohamad HE, Askar ME, Hafez MM (2011) Management of cardiac fibrosis in diabetic rats; the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) and calcium channel blockers (CCBs). Diabetol Metab Syndr 3:4. doi:10.1186/1758-5996-3-4
31. Arjumand W, Seth A, Sultana S (2011) Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFκB, TNF-α and caspase-3 expression in wistar rats. Food Chem Toxicol 49:2013–2021. doi:10.1016/j.fct.2011.05.012
32. Backes JM, Howard PA, Moriarty PM (2004) Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 38:110–118. doi:10.1345/aph.1D203
33. Ilkhanizadeh B, Shirpoor A, Khadem Ansari MH, Nemati S, Rasmi Y (2016) Protective effects of ginger (Zingiber officinale) extract against diabetes-induced heart abnormality in rats. Diabetes Metab J 40:46–53. doi:10.4093/dmj.2016.40.1.46
34. Dickstein K (2005) C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure. Eur Heart J 26:2218–2219. doi:10.1093/eurheartj/ehi464
35. Ronnow BS, Reyna SP, Muhlestein JB et al (2005) C-reactive protein predicts death in patients with non-ischemic cardiomyopathy. Cardiology 104:196–201. doi:10.1159/000088138
36. Whitsel EA, Boyko EJ, Rautaharju PM et al (2005) Electrocardiographic QT interval prolongation and risk of primary cardiac arrest in diabetic patients. Diabetes Care 28:2045–2047. doi:10.2337/diacare.28.8.2045
37. Veglio M, Giunti S, Stevens LK et al (2002) Prevalence of Q-T interval dispersion in type 1 diabetes and its relation with cardiac ischemia: the EURODIAB IDDM Complications Study Group. Diabetes Care 25:702–707. doi:10.2337/diacare.25.4.702
38. Earle KA, Mishra B, Morocutti A, Barnes D, Chambers J, Viberti GC (2000) QT dispersion in microalbuminuric Type 1 diabetic patients without myocardial ischemia. J Diabetes Complicat 14:277–280. doi:10.1016/S1056-8727(00)00123-9
39. Veglio M, Bruno G, Borra M et al (2002) Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med 251:317–324. doi:10.1046/j.1365-2796.2002.00955.x
40. Annapurna A, Reddy CS, Akondi RB, Rao SRC (2009) Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced type I diabetic rats. J Pharm Pharmacol 61:1365–1374. doi:10.1211/jpp/61.10.0014
41. Murdoch CE, Zhang M, Cave AC, Shah AM (2006) NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 71:208–215. doi:10.1016/j.cardiores.2006.03.016
42. Park JY, Ryu SK, Choi JW et al (2014) Association of inflammation, myocardial fibrosis and cardiac remodelling in patients with mild aortic stenosis as assessed by biomarkers and echocardiography. Clin Exp Pharmacol Physiol 41:185–191. doi:10.1111/1440-1681.12206
43. Zhang WB, Du QJ, Li H et al (2012) The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats. J Cell Mol Med 16:2227–2237. doi:10.1111/j.1582-4934.2012.01536.x